Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConvaTec Regulatory News (CTEC)

Share Price Information for ConvaTec (CTEC)

Share Price is delayed by 15 minutes
Get Live Data
209.40    5.40 (2.65%)
Bid:
209.20
Ask:
209.60
Spread: 0.40 (0.191%)
Market Cap: £4.09b
CTEC Live PriceLast checked at - London Stock Exchange

Intraday ConvaTec Share Chart

Director/PDMR Shareholding

12 Mar 2026 14:30

RNS Number : 4578W
Convatec Group PLC
12 March 2026
 

12 March 2026

Convatec Group Plc("Convatec" or "the Company")

Director/PDMR Shareholding 

The Company has been notified of the following transactions in relation to Persons Discharging Managerial Responsibility ("PDMR") in respect of ordinary shares of 10 pence each in the Company ("Shares").

1. Grant of Performance Share Awards

On 11 March 2026, the following conditional awards were granted to each of Jonny Mason, Chief Executive Officer and Fiona Ryder, Chief Financial Officer under the Convatec Group Omnibus Incentive Plan 2025 ("LTIP") in the form of Performance Share Awards ("PSA"). These PSA are due to vest on the third anniversary of grant at nil cost, conditional on the following performance conditions: organic revenue growth, three-year compound annualised growth in adjusted Earnings per Share, and three-year Relative Total Shareholder Return rank vs constituents of S&P Global Healthcare Equipment & Services index; and are subject to a two-year post vesting holding period:

Jonny Mason: 1,776,206

Fiona Ryder: 567,413

2. Grant of Deferred Bonus Awards

On the same date, the following conditional awards were granted to each of Jonny Mason and Fiona Ryder under the LTIP in the form of Deferred Bonus Awards ("DBA"). The DBA are due to vest on the third anniversary of grant at nil cost and are not subject to performance conditions:

Jonny Mason: 165,419

Fiona Ryder: 19,028

3. Grant of Restricted Share Awards

On the same date, the following conditional awards were granted to each of Jonny Mason and Fiona Ryder under the LTIP in the form of Restricted Share Awards ("RSA"). The RSA are due to vest on the third anniversary of grant at nil cost and are not subject to performance conditions:

Jonny Mason: 417,931

Fiona Ryder: 170,224

The preceding three-day average share price, closing on 10 March 2026, of £2.4167 was used in determining each of the awards made under the LTIP.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Jonny Mason

2

Reason for the notification

a)

Position/Status

Chief Executive Officer and PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Convatec Group Plc

b)

LEI

213800LS272L4FIDOH92

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Ordinary share of 10p each in Convatec Group Plc

 

Identification code

GB00BD3VFW73

b)

Nature of the transaction

a. Grant of PSA under the LTIP, subject to performance conditions.

b. Grant of DBA under the LTIP, subject to a time-based vesting period of three years.

c. Grant of RSA under the LTIP, subject to a time-based vesting period of three years.

 

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

a.

£0

1,776,206

b.

£0

165,419

c.

£0

417,931

d)

Aggregated information

- Aggregated volume 

- Price

 

2,359,556

£0

e)

Date of the transaction

2026-03-11

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Fiona Ryder

2

Reason for the notification

a)

Position/Status

Chief Financial Officer and PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Convatec Group Plc

b)

LEI

213800LS272L4FIDOH92

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Ordinary share of 10p each in Convatec Group Plc

 

Identification code

GB00BD3VFW73

b)

Nature of the transaction

a. Grant of PSA under the LTIP, subject to performance conditions.

b. Grant of DBA under the LTIP, subject to a time-based vesting period of three years.

c. Grant of RSA under the LTIP, subject to a time-based vesting period of three years.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

a.

£0

567,413

b.

£0

19,028

c.

 £0

170,224

d)

Aggregated information

- Aggregated volume 

- Price

 

756,665

£0

e)

Date of the transaction

2026-03-11

f)

Place of the transaction

Outside a trading venue

 

 

 

Enquiries

James Kerton Company Secretary Email: cosec@convatec.com

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

Classification: 2.2 Information disclosed under article 19 of the Market Abuse Regulation

About Convatec

 

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFEVVIIFLIR
Date   Source Headline
13th Sep 202212:08 pmEQSConvatec Group PLC: Scrip Dividend – Calculation Price
16th Aug 202212:00 pmEQSConvatec Group PLC: Director/PDMR Shareholding
16th Aug 202212:00 pmEQSConvatec Group PLC: Director/PDMR Shareholding
4th Aug 20227:00 amRNSInterim Results
7th Jul 202211:53 amRNSDirector Declaration
28th Jun 20225:26 pmRNSBlock listing Interim Review
31st May 20222:00 pmRNSTotal Voting Rights
19th May 202210:00 amRNSDirector/PDMR Shareholding
12th May 20224:25 pmRNSResult of AGM
12th May 20227:00 amRNSAGM Trading Update
4th May 20223:31 pmRNSScrip Dividend - Total Issued Shares
3rd May 20227:00 amRNSNotice of Forthcoming Scheduled IR Events
7th Apr 20223:45 pmRNSScrip Dividend – Calculation Price
1st Apr 20224:00 pmRNSHolding(s) in Company
31st Mar 20223:45 pmRNSTotal Voting Rights
30th Mar 202212:00 pmRNSAnnual Report and Accounts 2021 and Notice of AGM
25th Mar 20222:00 pmRNSDirector/PDMR Shareholding
23rd Mar 202211:30 amRNSDirector/PDMR Shareholding
17th Mar 20222:40 pmRNSDirector/PDMR Shareholding
17th Mar 20222:20 pmRNSBoard Change
14th Mar 20227:00 amRNSAcquisition Completion of Triad Life Sciences Inc
8th Mar 20227:00 amRNSAnnual Results
28th Feb 202211:00 amRNSNon-Executive Director Changes
10th Feb 20223:15 pmRNSHolding(s) in Company
28th Jan 20227:00 amRNSAcquisition: entry into attractive wound biologics
27th Jan 202211:00 amRNSBoard Committee Changes
20th Dec 20218:45 amRNSBlock Listing Application
16th Dec 20212:00 pmRNSNon-Executive Director appointment
9th Dec 20217:00 amRNSChief Financial Officer succession
1st Nov 20213:35 pmRNSTotal Voting Rights
29th Oct 20217:00 amRNSQ3 Trading Update
18th Oct 20214:30 pmRNSDirector/PDMR Shareholding
1st Oct 20217:00 amRNSPricing of $500M 3.875% Senior Notes due 2029
30th Sep 20211:13 pmRNSConvaTec Announces Offer of $500M Senior Notes
28th Sep 20213:15 pmRNSScrip Dividend - Total Issued Shares
9th Sep 20213:00 pmRNSScrip Dividend - Calculation Price
30th Jul 20213:45 pmRNSDirector/PDMR Shareholding
30th Jul 20217:00 amRNSInterim Results
28th Jun 202112:40 pmRNSDirector Declaration
1st Jun 202111:45 amRNSTotal Voting Rights
17th May 20213:15 pmRNSDirector/PDMR Shareholding
7th May 20212:50 pmRNSResult of AGM
29th Apr 20217:00 amRNSQ1 Trading Update
28th Apr 202112:45 pmRNSScrip Dividend - Total Issued Shares
12th Apr 20213:15 pmRNSScrip Dividend - Calculation Price
22nd Mar 20213:40 pmRNSAnnual Report and Accounts 2020 and Notice of AGM
11th Mar 20213:50 pmRNSDirector/PDMR Shareholding
5th Mar 20217:00 amRNSAnnual Results
22nd Feb 202111:30 amRNSDirector Declaration
21st Dec 202011:00 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.